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ABSTRACT
Introduction Laser trabeculoplasty is an effective
and widely used treatment for glaucoma. A new
laser technology, the Eagle direct selective laser
trabeculoplasty (DSLT) device, may provide automated,
fast, simple, safe and effective laser treatment for
glaucoma in a broader range of clinical settings.
This trial aims to test the hypothesis that translimbal
DSLT is effective and not inferior to selective laser
trabeculoplasty (SLT) in reducing intraocular pressure
(IOP) in open angle glaucoma (OAG).
Methods and analysis This is a multicentre,
randomised, controlled, investigator-masked study. The
primary efficacy outcome is intergroup difference in
mean change from baseline IOP measured at 6 months.
Secondary outcomes include mean percentage reduction
in IOP at 3, 6 and 12 months; proportion of participants
with at least 20% reduction in IOP from baseline at 6
months; change in ocular hypotensive medications at
12 months and evaluation of safety. Participants were
aged >= 40 years with OAG, including exfoliative or
pigmentary glaucoma, or ocular hypertension with
untreated or washed out IOP 22–35 mm Hg. Treatments:
DSLT: 120 shots, 3 ns, 400 µm spot size, energy 1.4–1.8
mJ delivered at the limbus over 2 s. SLT: approximately
100 shots, 3 ns, 400 µm spot size administered 360
degrees at the limbus using any gonioscopy lens, energy
0.3–2.6 mJ. A sample size of 164 is sufficient to detect
a non-inferiority margin of 1.95 mm Hg for change from
baseline IOP.
Clinical trial registration number NCT03750201,
ISRCTN14033075.
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Glaucoma is a chronic, initially asymptomatic
disease that may result in progressive optic nerve
damage. An estimated 76 million people suffer
from glaucoma worldwide,1 making it the leading
cause of irreversible blindness globally.2 Although
the damage is irreversible, further deterioration
(‘progression’) may be prevented or delayed by
reducing intraocular pressure (IOP). The goal of
glaucoma treatment is to maintain the patient’s
visual function with minimal impact on quality of
life, and ideally, in the most cost-effective fashion.

Treatment of glaucoma with topical hypotensive
medications depends on patient adherence and may
be associated with side effects, inconvenience and
financial burden to the patient. As a result, up to
50%–80% of patients fail to adhere to treatment
over a 12-month period.3 This study is addressing
the top research priority of the James Lind Alliance:
‘What are the most effective treatments for glaucoma and how can treatment be improved?’.4
Treatment of glaucoma with laser trabeculoplasty
(LTP), such as selective laser trabeculoplasty (SLT),
has been available for many years. Treatment with
SLT compared with medical treatment offers cost-
effective drop-
free disease control for 74% of
patients at 3 years when used as an initial therapy, as
reported in a large randomised controlled trial.5 The
IOP reduction effect is still present in 50% of patients
at 5 years, and treatment is repeatable.6 SLT targets
the trabecular meshwork (TM) and is designed to
reduce IOP by improving aqueous outflow. The
procedure lasts approximately 5–10 min and consists
of 50–100 separate laser ‘spots’ delivered through a
manually rotated mirrored lens (goniolens) placed
on the cornea. Although SLT is considered to be
a low-
risk procedure, the goniolens requires use
of a coupling gel and prolonged contact with the
patient’s eye that can result in epithelial damage,
blurred vision and discomfort, and carries a small
but significant infection risk. Although the effectiveness of SLT as an initial treatment for primary
open angle glaucoma (POAG) and ocular hypertension (OHT) has been demonstrated in clinical
trials,5 7 the procedure requires expertise which
limits its widespread use.
Recently, Geffen et al8 investigated the safety and
efficacy of performing translimbal SLT without the
use of a goniolens. In this small study, they were
able to show that this technique appeared to be as
efficacious as conventional SLT, however, taking
less time and possibly causing fewer complications,
possibly due to its non-contact methodology and
avoidance of transcorneal laser path.
The current protocol uses a new device, the
External Automatic Glaucoma Laser (Eagle): a
translimbal, direct selective laser trabeculoplasty
(DSLT) system. Non-
contact treatment automatically detects and directs laser energy through the
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METHODS

This is a multicentre, randomised, controlled, investigator-
masked trial designed to evaluate the relative safety and efficacy of translimbal DSLT compared with conventional SLT for
glaucoma.

Study outcomes

The primary efficacy outcome is the difference between the two
treatment groups between the mean (washed out for medicated
patients) baseline IOP and the mean (washed out for medicated patients) IOP measured at 6 months. Secondary efficacy
outcomes include between-group differences in mean percentage
reduction in IOP at 3, 6 and 12 months; the proportion of
participants with at least 20% reduction in IOP from baseline at
6 months; and the change in mean number of topical hypotensive medications at 12 months compared with baseline. All treatments will be administered by an unmasked ophthalmologist. All
post-randomisation IOP measures will either be collected using a
masked technique or by a masked ophthalmologist.
Safety measures include all ocular adverse events (AEs). Quality
of life and patient satisfaction will be evaluated with the Glaucoma
Quality of Life (GQL-9)9 10 and a standardised questionnaire.

Ethics and regulatory approvals

The trial will be conducted according to the World Medical Association Declaration of Helsinki and is in receipt of full regulatory
authority and research ethics committee (REC) approval in each
country and site. The protocol is prospectively registered on a
publicly accessible database (Protocol # 2017_01, C
 lintrials.gov #
NCT03750201, ISRCTN14033075). Potential participants will be
provided with the REC-approved patient information sheet, and
given sufficient time to review and ask questions before providing
written informed consent ahead of any study procedures.

Study population

The study population comprises participants aged over 40 years
with OAG, including exfoliative or pigmentary glaucoma, or
OHT who are able to give informed consent to participate for
12 months. IOP at randomisation must fall between 22 and 35
mm Hg inclusive in either an untreated or washed-
out state.
Participants must have gonioscopically visible scleral spur for
360 degrees and clear visualisation of the perilimbal sclera for
360 degrees with a vertical cup to disc ratio of less than 0.8.
Patients with contraindications to SLT are excluded as are
patients with angle closure glaucoma, congenital or developmental glaucoma, secondary glaucoma (except exfoliative or
pigmentary glaucoma) or those with the presence of any peripheral anterior synechiae in the study eye. Patients must be able to
undertake a reliable visual field test (defined as fixation losses,
false positives and false negatives less than 33%). Any of the
following visual field findings using the Humphrey visual field
(HVF) analyser and Swedish Interactive Thresholding Algorithm
(SITA) standard 24-2 programme would exclude a patient: a
visual field mean deviation of less than −12 dB, greater than 75%
of points depressed below the 5% level and greater than or equal
to 50% of points depressed below the 1% level on the pattern
deviation plot, at least 50% of points, that is, 2 or more, within
the central 5 degrees with a sensitivity of 0 dB on the decibel
plot and points within the central 5 degrees of fixation with a
sensitivity greater than 15 dB in both hemifields on the decibel

plot. The mean defect in the fellow eye must be greater than
−12 dB. Participants must not have any other clinically significant disease in either eye, prior incisional glaucoma surgery in
the study eye, any significant cataract or cataract surgery in the
last 6 months, prior corneal refractive surgery, prior SLT, significant amblyopia or dense pigmentation or haemorrhage in the
perilimbal conjunctiva or anterior sclera. Other exclusions will
include pregnancy, participation in another clinical trial other
than a substudy of this trial, clinically relevant systemic disease
or the anticipated need for other ocular surgery.

Device description

DSLT is a treatment modality for POAG, which uses similar laser
parameters as SLT and has similar treatment indications. As in
SLT, DSLT employs frequency-
doubled, Q-
switched Nd:YAG
laser with a wavelength of 532 nm. During the procedure, laser
energy is delivered to the TM. This increases the permeability of
the TM endothelial cells and thereby increases outflow, resulting
in reduced IOP. In contrast to SLT, the DSLT treatment uses
the Eagle system to direct the laser energy directly through the
limbus to the TM without the need for a delivery device (gonioscopy lens) or any contact with the participant’s eye. Laser energy
is administered through a full 360 degrees, almost completely
automatically by the Eagle system, with only the operator’s
rough alignment of the eye and approval of the device’s automatically acquired target. Laser treatment lasts for about 2 s with
120 laser pulses of preset 3 ns and a preset 400 µm spot size will
be used, with the laser energy of 1.4–1.8 mJ delivered to the
limbus. For the SLT, approximately 100 shots of a preset 3 ns
duration and a preset 400 µm spot size will be used 360 degrees
around the limbus, with the laser energy varied from 0.3 to 2.6
mJ by the clinician using any laser gonioscopy lens.
The trial has started using the prototype device, which was
used in the first human study.9 During this trial, the Eagle system
became available. The Eagle system has the same functionality as
the prototype, but with increased usability, namely, the device is
now a smaller and lighter table top unit.

Enrolment, randomisation and data acquisition

Randomisation will be per site, with lists generated as a 1:1
random algorithm by the study statistician (two sequences
according to whether or not the participant is receiving beta-
blockers) and sealed envelopes provided to site. All treatments
will be administered by unmasked ophthalmologists, although
masked investigators will collect post randomisation IOP and
study assessments. It is not possible to mask participants due to
the varying nature of the two treatments. Figure 1 summarises
the study design and patient flow.
After providing written informed consent, potential participants will be screened to ensure eligibility.
At this visit, the following examinations will be performed on
both eyes:
► Goldmann applanation tonometry.
► Corrected visual acuity (CVA) using the ETDRS alphabet
chart on a backlit light box.
► Slit-lamp examination of the anterior segment.
► Gonioscopy.
► Fundus examination.
► HVF examination using the 24-2 SITA standard programme.
► Recording of current ocular hypotensive medications and
systemic medications (type and dosage).
If a participant is currently using topical ocular medications,
IOP will be reassessed in a post-washout visit after a washout
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limbus overlying the TM. The entire 360 degrees of the TM is
treated simultaneously in about 2 s.
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period of length determined by the type of medication(s) being
used (up to 28 days).
During the washout period, additional visits can be conducted
at the discretion of the investigator, to ensure continued safety,
particularly for patients considered at risk for an unacceptably
high IOP spike during washout.
If during one of these visits it is found that the participant’s
IOP increases to an unsafe level (at the investigators’ discretion),
ocular hypotensive medication will be reintroduced and they
will be followed for safety until any AEs are resolved or stabilised, and then exited from the study.
Following washout, the eligibility of patients is confirmed and
the threshold IOP value is determined by the investigators’ clinical judgement. Participants will then be randomised 1:1 to SLT
or DSLT. If both eyes are washed out and found to be eligible
for inclusion, the principal investigator will enrol the eye with
the highest post-washout IOP. If both eyes have the same IOP,
the eye with the more advanced disease will be chosen. Standard
glaucoma treatment will be (re)initiated in the non-study eye at
the discretion of the investigator.

Study interventions

As a prophylaxis against laser-induced IOP elevation, apraclonidine or brimonidine drops will be administered (45–60 min and
10 min before treatment) as well as a drop of pilocarpine (60 min
before treatment).
Following treatment, the following assessments will be made
on the study eye only:
► IOP immediately following treatment.
► IOP 1–2 hours after treatment (additional care at the discretion of the investigator).
► CVA using ETDRS.
► Slit-
lamp examination with grading of anterior chamber
cells (0 to +4) and flare (0 to +4).
Patients will be asked to provide feedback following treatment
to assess satisfaction, pain and willingness to undergo the treatment again (graded using a Likert scale).
64

Statistical analyses and sample size calculation

A total of 164 patients will be required to reject a non-inferiority
null hypothesis that DSLT change-from-baseline IOP is more
than 1.95 mm Hg worse (less) than the SLT change-
from-
baseline IOP. The primary hypothesis will be tested at 6months
post-treatment using the estimated difference in change-from-
baseline IOP between study groups (DSLT and SLT) with 80%
power and the associated 95% two-sided CI, a fitted analysis of
covariance (ANCOVA) model will adjust for baseline IOP and
for the use of beta-blocker drops in the fellow eye.
The sample size calculation was based on a non-inferiority
margin of 1.95 mm Hg and an anticipated SD of 3.5.10 The non-
inferiority margin of 1.95 mm Hg was chosen based on clinical
judgement as IOP measurement differences of up to 2 mm Hg are
considered to be non-clinically significant.11 12 Other literature
reports a predefined non-inferiority margin of 1–2.5 mm Hg.13
The mean percentage reduction in IOP from baseline will be
summarised by treatment group at 3, 6 and 12 months after enrolment. The proportion of participants with at least 20% reduction in
IOP from baseline will be summarised at 6 months with associated
95% CI. The mean number of medications will be calculated for each
group before treatment and at 12 months, and compared between
groups. The GQL-9 questionnaire results will be summarised in
appropriate tables by treatment group.
AEs will be coded and presented according to relatedness,
severity and seriousness. Rates of AEs (on a per person basis) will be

Congdon N, et al. Br J Ophthalmol 2023;107:62–65. doi:10.1136/bjophthalmol-2021-319379

Br J Ophthalmol: first published as 10.1136/bjophthalmol-2021-319379 on 25 August 2021. Downloaded from http://bjo.bmj.com/ on January 4, 2023 at Thomas Jefferson University.
Protected by copyright.

Figure 1 Flowchart depicting the enrolment and progression of
participants through the trial. DSLT, direct selective laser trabeculoplasty;
IOP, intraocular pressure; SLT, selective laser trabeculoplasty.

Following the treatment, participants will be instructed to
use topical non-steroidal anti-inflammatory medications in the
treated eye for 1 week at the discretion of the investigator.
up and assessment visits are planned at
Scheduled follow-
1 day, 1 week, and 1, 3, 6 and 12 months following treatment.
Patients receiving glaucoma medications will be asked to stop
these 28 days before the 6-month visit.
Gonioscopic examination will be repeated at the 6-
month
follow-up visit to detect any changes to the anterior chamber
angle after the laser treatment.
At each visit, the IOP will be assessed and compared with the
threshold IOP limit value, if this value is reached, topical hypotensive medications will be initiated, starting with prostaglandin, then
beta-blocker and other medications according to standard of care.
Patients will be asked to repeat the GQL-9 questionnaire at
the 6-month visit and they will assess their willingness to repeat
the treatment and whether they would recommend the treatment to a friend with glaucoma.
Treatment modification will be allowed for safety reasons if
IOP becomes uncontrolled after treatment. There will be no
reintroduction of medication for at least 1 month after treatment
unless, in the opinion of the investigator, there is immediate risk
to the health of the participant.
If cataract surgery, trabeculectomy or any other glaucoma
surgery is required during the study follow-up period, the participant will undergo such treatment as deemed necessary (at the
discretion of the investigator) and will be considered a treatment
failure. She/he will continue to be followed up in the study glaucoma clinics thereafter.
Safety will be evaluated throughout the study consisting of
recording of all AEs. An independent medical monitor will
be responsible for overseeing safety and for evaluating all
AEs reported to the sponsor. AEs and serious AEs are defined
according to the International Conference on Harmonization
E6 (R2) and International Organization for Standardization
14155:2011(E) definition.

Clinical science
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CONCLUSION

Laser trabeculoplasty is an approved treatment available to
patients with OAG that can be used with or without ocular hypotensive medication to reduce IOP. The safety and effectiveness of
SLT has been well demonstrated in prior studies.13–16 Due to its
IOP-lowering effect, SLT may result in a decrease or elimination of ocular hypotensive medications. SLT may cause inflammatory reactions, including cystoid macular oedema and, more
commonly, anterior chamber inflammation.17–19 The inflammation is usually mild to moderate in its severity and transient, with
reductions in intensity seen within 24 hours post-treatment, and
resolution in most eyes within 5 days.20
Another risk associated with SLT is the occurrence of postoperative IOP elevation. This usually occurs in the immediate
postoperative phase (1–2 hours) and careful patient selection and
prophylactic treatment can greatly reduce their occurrence.21
DSLT is performed without physically touching the cornea,
and preliminary studies have shown that it is a more rapid
and simpler technique when compared with SLT.8 Further, it
has been suggested that it could be more easily administered
in patients in whom contact techniques prove problematic or
where anatomical obstacles exist, such as narrow iridocorneal
angles or prominent facial bones.8 The same study demonstrated
similar IOP-lowering effect in both DSLT and SLT, and suggested
that DSLT resulted in less corneal injury, inflammation and postoperative discomfort when compared with standard SLT.
Benefits of DSLT may include a faster and simpler treatment,
less postoperative inflammation and less subjective discomfort.
In addition, the procedure does not require use of a goniolens
and therefore has the potential to increase the accessibility of
glaucoma care throughout the world. This study will determine
the efficacy and safety of the new Eagle system.
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calculated, and 95% CIs for the rates, and for the difference between
treatment groups, will be produced using score-based methods.

